X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (101437) 101437
Publication (7233) 7233
Newsletter (2362) 2362
Book Review (1014) 1014
Newspaper Article (991) 991
Book Chapter (650) 650
Magazine Article (179) 179
Conference Proceeding (147) 147
Book / eBook (113) 113
Dissertation (107) 107
Trade Publication Article (38) 38
Web Resource (33) 33
Transcript (17) 17
Reference (14) 14
Data Set (11) 11
Government Document (10) 10
Paper (3) 3
Presentation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (70016) 70016
male (33889) 33889
index medicus (32399) 32399
animals (30393) 30393
female (27261) 27261
middle aged (18510) 18510
platelet aggregation inhibitors - therapeutic use (18186) 18186
aged (15185) 15185
hematology (13186) 13186
adult (12538) 12538
platelet aggregation - drug effects (11582) 11582
platelets (10699) 10699
cardiac & cardiovascular systems (10663) 10663
peripheral vascular disease (10126) 10126
blood platelets - metabolism (9613) 9613
blood platelets - drug effects (9561) 9561
platelet aggregation inhibitors - pharmacology (9224) 9224
rats (9173) 9173
pharmacology & pharmacy (9097) 9097
mice (8767) 8767
blood platelets (8735) 8735
treatment outcome (8525) 8525
aspirin (8328) 8328
risk factors (8243) 8243
biochemistry & molecular biology (8096) 8096
ticlopidine - analogs & derivatives (7445) 7445
platelet aggregation inhibitors - administration & dosage (7280) 7280
time factors (6890) 6890
thrombosis (6833) 6833
aspirin - therapeutic use (6727) 6727
cell biology (6440) 6440
clopidogrel (6413) 6413
platelet aggregation inhibitors - adverse effects (6167) 6167
activation (6103) 6103
platelet-derived growth factor (6078) 6078
cells, cultured (5849) 5849
platelet aggregation (5823) 5823
research (5734) 5734
in vitro techniques (5664) 5664
analysis (5603) 5603
dose-response relationship, drug (5562) 5562
aggregation (5239) 5239
expression (5002) 5002
ticlopidine - therapeutic use (4600) 4600
surgery (4576) 4576
care and treatment (4549) 4549
drug therapy, combination (4525) 4525
inhibition (4437) 4437
anticoagulants - therapeutic use (4430) 4430
aged, 80 and over (4358) 4358
blood platelets - physiology (4305) 4305
inflammation (4124) 4124
phosphorylation (4048) 4048
oncology (3997) 3997
medicine, general & internal (3977) 3977
signal transduction (3923) 3923
abridged index medicus (3921) 3921
platelet activation (3904) 3904
percutaneous coronary intervention (3816) 3816
risk (3806) 3806
therapy (3699) 3699
stents (3680) 3680
proteins (3644) 3644
platelet (3621) 3621
rabbits (3576) 3576
stroke (3520) 3520
mortality (3493) 3493
prospective studies (3491) 3491
cancer (3478) 3478
health aspects (3419) 3419
thrombin (3418) 3418
aspirin - administration & dosage (3407) 3407
myocardial-infarction (3377) 3377
disease (3336) 3336
cells (3259) 3259
platelet glycoprotein gpiib-iiia complex - antagonists & inhibitors (3239) 3239
kinetics (3184) 3184
prevention (3145) 3145
article (3140) 3140
retrospective studies (3115) 3115
drug therapy (3112) 3112
acute coronary syndromes (3100) 3100
atherosclerosis (3063) 3063
anticoagulants (3044) 3044
blood (3039) 3039
medicine, research & experimental (3036) 3036
medicine & public health (3024) 3024
platelet count (3009) 3009
physiological aspects (2964) 2964
research article (2940) 2940
medicine (2857) 2857
aspirin - pharmacology (2856) 2856
cardiology (2848) 2848
immunology (2823) 2823
in-vitro (2784) 2784
platelet activation - drug effects (2748) 2748
follow-up studies (2720) 2720
platelet-aggregation (2715) 2715
antiplatelet therapy (2646) 2646
blood platelets - enzymology (2617) 2617
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (74) 74
Online Resources - Online (33) 33
Collection Dvlpm't (Acquisitions) - Vendor file (7) 7
Collection Dvlpm't (Acquisitions) - Closed Orders (3) 3
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (3) 3
Scarborough Hospital - General (1) 1
St. Michael's Hospital - Stacks (1) 1
UofT at Scarborough - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (99857) 99857
German (1257) 1257
French (891) 891
Japanese (781) 781
Russian (704) 704
Spanish (542) 542
Chinese (520) 520
Italian (321) 321
Polish (197) 197
Dutch (88) 88
Portuguese (84) 84
Danish (57) 57
Hungarian (56) 56
Korean (54) 54
Swedish (53) 53
Czech (51) 51
Turkish (45) 45
Norwegian (35) 35
Hebrew (22) 22
Serbian (18) 18
Ukrainian (18) 18
Finnish (16) 16
Romanian (13) 13
Lithuanian (11) 11
Slovak (11) 11
Croatian (9) 9
Icelandic (4) 4
Bosnian (2) 2
Bulgarian (2) 2
Persian (2) 2
Latvian (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9798, pp. 1231 - 1243
Summary Background Although most cardiovascular disease occurs in low-income and middle-income countries, little is known about the use of effective secondary... 
Internal Medicine | STROKE | MEDICINE, GENERAL & INTERNAL | RISK-FACTORS | THERAPY | MYOCARDIAL-INFARCTION | AVAILABILITY | HEART-FAILURE | SELF-REPORT | ACUTE CORONARY SYNDROMES | MEDICINES | VALIDITY | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Male | Data Collection | Secondary Prevention | Stroke - drug therapy | Urban Population | Antihypertensive Agents - therapeutic use | Drug Utilization | Cardiovascular Agents - therapeutic use | Developed Countries | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Rural Population | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Coronary Disease - drug therapy | Adult | Female | Aged | Developing Countries | Platelet Aggregation Inhibitors - therapeutic use | Adrenergic beta-Antagonists - therapeutic use | Care and treatment | Research | Cardiovascular diseases | Health aspects | Cardiovascular agents | Studies | Low income groups | Stroke | Households | Socioeconomic factors | Data collection | Cardiovascular disease | Epidemiology | Economic development | Community | Drug use | Antihypertensive Agents/therapeutic use | Angiotensin-Converting Enzyme Inhibitors/therapeutic use | Cardiovascular Agents/therapeutic use | Coronary Disease/drug therapy | Cardiovascular Diseases/prevention & control | Platelet Aggregation Inhibitors/therapeutic use | Stroke/drug therapy | MEDICIN OCH HÄLSOVETENSKAP | Adrenergic beta-Antagonists/therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use | MEDICAL AND HEALTH SCIENCES
Journal Article
by Anand, Sonia S and Bosch, Jackie and Eikelboom, John W and Connolly, Stuart J and Diaz, Rafael and Widimsky, Peter and Aboyans, Victor and Alings, Marco and Kakkar, Ajay K and Keltai, Katalin and Maggioni, Aldo P and Lewis, Basil S and Störk, Stefan and Zhu, Jun and Lopez-Jaramillo, Patricio and O'Donnell, Martin and Commerford, Patrick J and Vinereanu, Dragos and Pogosova, Nana and Ryden, Lars and Fox, Keith A A and Bhatt, Deepak L and Misselwitz, Frank and Varigos, John D and Vanassche, Thomas and Avezum, Alvaro A and Chen, Edmond and Branch, Kelley and Leong, Darryl P and Bangdiwala, Shrikant I and Hart, Robert G and Yusuf, Salim and SALA, JORGELINA and CARTASEGNA, LUIS and VICO, MARISA and HOMINAL, MIGUEL ANGEL and HASBANI, EDUARDO and CACCAVO, ALBERTO and ZAIDMAN, CESAR and VOGEL, DANIEL and HRABAR, ADRIAN and SCHYGIEL, PABLO OMAR and CUNEO, CARLOS and LUQUEZ, HUGO and MACKINNON, IGNACIO J and AHUAD GUERRERO, RODOLFO ANDRES and COSTABEL, JUAN PABLO and BARTOLACCI, INES PALMIRA and MONTANA, OSCAR and BARBIERI, MARIA and GOMEZ VILAMAJO, OSCAR and GARCIA DURAN, RUBEN OMAR and SCHIAVI, LILIA BEATRIZ and GARRIDO, MARCELO and INGARAMO, ADRIAN and BORDONAVA, ANSELMO PAULINO and PELAGAGGE, MARIA JOSE and NOVARETTO, LEONARDO and ALBISU DI GENNERO, JUAN PABLO and IBANEZ SAGGIA, LUZ MARIA and ALVAREZ, MOIRA and VITA, NESTOR ALEJANDRO and MACIN, STELLA MARIS and DRAN, RICARDO DARIO and CARDONA, MARCELO and GUZMAN, RANDOLPH and GUZMAN, LUIS and SARJANOVICH, RODOLFO JUAN and CUADRADO, JESUS and NANI, SEBASTIAN and LITVAK BRUNO, MARCOS RAUL and CHACON, CAROLINA and MAFFEI, LAURA ELENA and GRINFELD, DIEGO and VENSENTINI, NATALIA and MAJUL, CLAUDIO RODOLFO and LUCIARDI, HECTOR LUCAS and GONZALEZ COLASO, PATRICIA DEL CARMEN and FERRE PACORA, FREDY ANTONI and VAN DEN HEUVEL, PAUL and VERHAMME, PETER and ECTOR, BAVO and DEBONNAIRE, PHILIPPE and VAN DE BORNE, PHILIPPE and LEROY, JEAN and SCHROE, HERMAN and VRANCKX, PASCAL and ELEGEERT, IVAN and HOFFER, ETIENNE and DUJARDIN, KARL and INDIO DO BRASIL, CLARISSE and PRECOMA, DALTON and ABRANTES, JOSE ANTONIO and MANENTI, EULER and REIS, GILMAR and SARAIVA, JOSE and MAIA, LILIA and HERNANDES, MAURO and ROSSI, PAULO and ROSSI DOS SANTOS, FABIO and ... and COMPASS Investigators and Sahlgrenska akademin and Institute of Medicine, Department of Molecular and Clinical Medicine and Institutionen för medicin, avdelningen för molekylär och klinisk medicin and Göteborgs universitet and Gothenburg University and Sahlgrenska Academy
The Lancet, ISSN 0140-6736, 01/2018, Volume 391, Issue 10117, pp. 219 - 229
Patients with peripheral artery disease have an increased risk of cardiovascular morbidity and mortality. Antiplatelet agents are widely used to reduce these... 
MORTALITY | MEDICINE, GENERAL & INTERNAL | METAANALYSIS | MANAGEMENT | THERAPY | OUTPATIENTS | CARDIOVASCULAR EVENT RATES | PREVENTION | RISK | Myocardial Infarction - epidemiology | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Carotid Artery Diseases - complications | Male | Peripheral Arterial Disease - complications | Rivaroxaban - administration & dosage | Aspirin - administration & dosage | Factor Xa Inhibitors - administration & dosage | Incidence | Dose-Response Relationship, Drug | Rivaroxaban - adverse effects | Aspirin - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Cardiovascular Diseases - mortality | Female | Stroke - epidemiology | Aspirin - therapeutic use | Lower Extremity - surgery | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Myocardial Infarction - etiology | Rivaroxaban - therapeutic use | Carotid Artery Diseases - drug therapy | Platelet Aggregation Inhibitors - adverse effects | Stroke - prevention & control | Double-Blind Method | Drug Administration Schedule | Peripheral Arterial Disease - drug therapy | Carotid Artery Diseases - epidemiology | Morbidity | Factor Xa Inhibitors - therapeutic use | Stroke - etiology | Peripheral Arterial Disease - epidemiology | Factor Xa Inhibitors - adverse effects | Aged | Myocardial Infarction - prevention & control | Amputation - statistics & numerical data | Hemorrhage - chemically induced | Lower Extremity - blood supply | Cardiac arrhythmia | Anticoagulants | Aspirin | Stroke | Heart attacks | Medical imaging | Mortality | Clinical trials | Cardiovascular disease | Patients | Disease control | Carotid arteries | Disease prevention | Coronary vessels | Blood pressure | Carotid artery | Acute coronary syndromes | Thromboembolism | Health risk assessment | Cardiovascular Diseases | Factor Xa Inhibitors | Klinisk medicin | Hemorrhage | epidemiology | Rivaroxaban | administration & dosage | Combination | Amputation | Drug | drug therapy | chemically induced | complications | prevention & control | Peripheral Arterial Disease | etiology | Clinical Medicine | Myocardial Infarction | statistics & numerical data | blood supply | Carotid Artery Diseases | Platelet Aggregation Inhibitors | adverse effects | mortality | Lower Extremity | Dose-Response Relationship | therapeutic use | surgery
Journal Article
Hepatology, ISSN 0270-9139, 01/2018, Volume 67, Issue 1, pp. 247 - 259
Journal Article
International Journal of Molecular Sciences, ISSN 1661-6596, 2014, Volume 15, Issue 8, pp. 13768 - 13801
Chemotherapeutic and cytotoxic drugs are widely used in the treatment of cancer. In spite of the improvements in the life quality of patients, their... 
Small-molecule inhibitors | Targeted cancer therapy | Receptor tyrosine kinases | Tyrosine kinase inhibitors | targeted cancer therapy | PAN-ERBB INHIBITOR | BIOCHEMISTRY & MOLECULAR BIOLOGY | ACUTE MYELOGENOUS LEUKEMIA | HEPATOCYTE GROWTH-FACTOR | ACUTE MYELOID-LEUKEMIA | ANTITUMOR-ACTIVITY | CHEMISTRY, MULTIDISCIPLINARY | tyrosine kinase inhibitors | CELL LUNG-CANCER | PHASE-II TRIAL | receptor tyrosine kinases | CHRONIC LYMPHOCYTIC-LEUKEMIA | TUMOR-GROWTH | C-MET INHIBITOR | small-molecule inhibitors | fms-Like Tyrosine Kinase 3 - antagonists & inhibitors | Receptors, Platelet-Derived Growth Factor - antagonists & inhibitors | Humans | Receptors, Fibroblast Growth Factor - antagonists & inhibitors | Small Molecule Libraries - therapeutic use | Drug Resistance, Neoplasm | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - chemistry | Receptor Protein-Tyrosine Kinases - metabolism | fms-Like Tyrosine Kinase 3 - metabolism | Neoplasms - drug therapy | Small Molecule Libraries - chemistry | Protein Kinase Inhibitors - chemistry | Receptor, Epidermal Growth Factor - metabolism | Receptors, Vascular Endothelial Growth Factor - metabolism | Protein Kinase Inhibitors - therapeutic use | Receptors, Platelet-Derived Growth Factor - metabolism | Receptors, Fibroblast Growth Factor - metabolism | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors | Pharmacology | Inhibitor drugs | Kinases | Cancer
Journal Article
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 01/2011, Volume 89, Issue 1, pp. 65 - 74
Four randomized, placebo‐controlled, crossover studies were conducted among 282 healthy subjects to investigate whether an interaction exists between... 
VARIABILITY | LANSOPRAZOLE | RABEPRAZOLE | THERAPY | CARDIOVASCULAR EVENTS | STENT PLACEMENT | PHARMACOLOGY & PHARMACY | OUTCOMES | ANTIPLATELET ACTION | PROTON-PUMP INHIBITORS | DRUG-INTERACTION | Proton Pump Inhibitors - pharmacology | Ticlopidine - pharmacology | Humans | Middle Aged | Half-Life | Male | 2-Pyridinylmethylsulfinylbenzimidazoles - pharmacology | Enzyme Inhibitors - administration & dosage | Platelet Aggregation Inhibitors - blood | Young Adult | Drug Interactions | Proton Pump Inhibitors - administration & dosage | Platelet Aggregation Inhibitors - pharmacology | Adult | Female | Omeprazole - pharmacology | Platelet Aggregation - drug effects | Platelet Aggregation Inhibitors - pharmacokinetics | Ticlopidine - pharmacokinetics | Enzyme Inhibitors - adverse effects | Proton Pump Inhibitors - adverse effects | Aryl Hydrocarbon Hydroxylases - antagonists & inhibitors | Double-Blind Method | Drug Administration Schedule | 2-Pyridinylmethylsulfinylbenzimidazoles - adverse effects | Omeprazole - administration & dosage | Enzyme Inhibitors - pharmacology | Omeprazole - adverse effects | Ticlopidine - analogs & derivatives | Cross-Over Studies | Prodrugs - adverse effects | Prodrugs - pharmacokinetics | Cytochrome P-450 CYP2C19 | Platelet Activation - drug effects | 2-Pyridinylmethylsulfinylbenzimidazoles - administration & dosage | Prodrugs - pharmacology | Ticlopidine - blood | Omeprazole | Pantoprazole | Drug interactions | Analysis | Dosage and administration | Research | Patients | Health aspects
Journal Article